212 related articles for article (PubMed ID: 17470153)
1. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.
Matsumoto A; Haraguchi K; Takahashi T; Azuma T; Kanda Y; Tomita K; Kurokawa M; Ogawa S; Takahashi K; Chiba S; Kitamura T
Int J Urol; 2007 Apr; 14(4):277-83. PubMed ID: 17470153
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
3. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
Höltl L; Zelle-Rieser C; Gander H; Papesh C; Ramoner R; Bartsch G; Rogatsch H; Barsoum AL; Coggin JH; Thurnher M
Clin Cancer Res; 2002 Nov; 8(11):3369-76. PubMed ID: 12429623
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
[TBL] [Abstract][Full Text] [Related]
6. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
[TBL] [Abstract][Full Text] [Related]
8. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study.
Ovali E; Dikmen T; Sonmez M; Yilmaz M; Unal A; Dalbasti T; Kuzeyli K; Erturk M; Omay SB
J Exp Clin Cancer Res; 2007 Jun; 26(2):209-14. PubMed ID: 17725100
[TBL] [Abstract][Full Text] [Related]
9. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma.
Tatsugami K; Eto M; Harano M; Hamaguchi M; Miyamoto T; Morisaki T; Furue M; Akashi K; Naito S
Int J Urol; 2008 Aug; 15(8):694-8. PubMed ID: 18564205
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial.
Märten A; Flieger D; Renoth S; Weineck S; Albers P; Compes M; Schöttker B; Ziske C; Engelhart S; Hanfland P; Krizek L; Faber C; von Ruecker A; Müller S; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2002 Dec; 51(11-12):637-44. PubMed ID: 12439609
[TBL] [Abstract][Full Text] [Related]
12. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
Hegmans JP; Veltman JD; Lambers ME; de Vries IJ; Figdor CG; Hendriks RW; Hoogsteden HC; Lambrecht BN; Aerts JG
Am J Respir Crit Care Med; 2010 Jun; 181(12):1383-90. PubMed ID: 20167848
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E
J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362
[TBL] [Abstract][Full Text] [Related]
16. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Soleimani A; Berntsen A; Svane IM; Pedersen AE
Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
[TBL] [Abstract][Full Text] [Related]
17. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience.
Azuma T; Horie S; Tomita K; Takahashi T; Tanaka Y; Kashiwase K; Nieda M; Takeuchi T; Ohta N; Shibata Y; Hirai H; Kitamura T
Int J Urol; 2002 Jun; 9(6):340-6. PubMed ID: 12110099
[TBL] [Abstract][Full Text] [Related]
20. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
Verra N; de Jong D; Bex A; Batchelor D; Dellemijn T; Sein J; Nooijen W; Meinhardt W; Horenblas S; de Gast G; Vyth-Dreese F
Eur Urol; 2005 Sep; 48(3):527-33. PubMed ID: 16115526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
